Involvement of the TGFβ pathway in the regulation of α 5β 1 integrins by caveolin-1 in human glioblastoma

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages 601-611

  Cosset, Erika C ^a   Godet, Julien ^a,b   Entz Werlé, Natacha ^c,d   Guérin, Eric ^c,d   Guenot, Dominique ^d   Froelich, Sébastien ^e   Bonnet, Dominique ^a   Pinel, Sophie ^f   Plenat, François ^f   Chastagner, Pascal ^g   Dontenwill, Monique ^a   Martin, Sophie ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Département d'Informations Médicales   (France)

^c Hôpitaux universitaires de Strasbourg laboratoire de biochimie et biologie moléculaire   (France)

^d EA4438   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f UNIVERSITÉ DE LORRAINE   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

biopsies; caveolin 1; glioblastoma; integrins; treatment

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; CAVEOLIN 1; K 34C; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHA5BETA1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861557472     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26415     Document Type: Article

References (42)

1. van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K,. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 2003; 13: 92-100.
2. Torres VA, Tapia JC, Rodriguez DA, Parraga M, Lisboa P, Montoya M, Leyton L, Quest AF,. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 2006; 119: 1812-23.
3. Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L,. Caveolin and cancered. Totowa, New Jersey, USA: Humana Press, 2005.
4. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA, Lisanti MP,. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 2006; 168: 1998-2013.
5. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, Pestell RG,. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 2000; 275: 21203-9.
6. Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H,. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp Cell Res 2006; 312: 3899-908.
7. Glait C, Ravid D, Lee SW, Liscovitch M, Werner H,. Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells. FEBS Lett 2006; 580: 5268-74.
8. Carver LA, Schnitzer JE,. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003; 3: 571-81.
9. Grossman SA, Batara JF,. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635-44.
10. Boon K, Edwards JB, Eberhart CG, Riggins GJ,. Identification of astrocytoma associated genes including cell surface markers. BMC Cancer 2004; 4: 39.
11. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J,. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000; 60: 6617-22.
12. Van Meter T, Dumur C, Hafez N, Garrett C, Fillmore H, Broaddus WC,. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 2006; 15: 195-205.
13. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-35.
14. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65: 1678-86.
15. Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A,. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol 2007; 31: 760-9.
16. Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, Dontenwill M,. Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta 2009; 1793: 354-67.
17. Heckmann D, Meyer A, Marinelli L, Zahn G, Stragies R, Kessler H,. Probing integrin selectivity: rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor. Angew Chem Int Ed Engl 2007; 46: 3571-4.
18. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
19. Bader BL, Rayburn H, Crowley D, Hynes RO,. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95: 507-19.
20. Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin JL, Delmas C, Plenat F, Chastagner P,. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 2004; 59: 250-9.
21. Fong YC, Hsu SF, Wu CL, Li TM, Kao ST, Tsai FJ, Chen WC, Liu SC, Wu CM, Tang CH,. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer 2009; 64: 13-21.
22. Heino J, Massague J,. Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem 1989; 264: 21806-11.
23. Paulus W, Baur I, Huettner C, Schmausser B, Roggendorf W, Schlingensiepen KH, Brysch W,. Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp Neurol 1995; 54: 236-44.
24. Wang B, Li S, Southern PJ, Cleary PP,. Streptococcal modulation of cellular invasion via TGF-beta1 signaling. Proc Natl Acad Sci USA 2006; 103: 2380-5.
25. Zhang G, Cao Y, Xu Y, See WA,. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma. Urol Oncol 2005; 23: 413-8.
26. Funaba M, Zimmerman CM, Mathews LS,. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 2002; 277: 41361-8.
27. Platten M, Wick W, Weller M,. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001; 52: 401-10.
28. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkiewicz K, Chouaib S, Kaminska B,. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion - an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 2008; 27: 918-30.
29. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J,. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007; 11: 147-60.
30. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954-61.
31. Kaminska B, Wesolowska A, Danilkiewicz M,. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005; 52: 329-37.
32. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN,. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004; 3: 737-45.
33. Akhurst RJ,. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006; 7: 513-21.
34. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM,. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104: 496-503.
35. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008; 68: 2329-39.
36. Maglott A, Bartik P, Cosgun S, Klotz P, Ronde P, Fuhrmann G, Takeda K, Martin S, Dontenwill M,. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res 2006; 66: 6002-7.
37. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A,. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000; 60: 309-20.
38. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S, Dontenwill M,. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 2010; 127: 1240-8.
39. Xu XL, Kapoun AM,. Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes. J Transl Med 2009; 7: 12.
40. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF,. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64: 6503-10.
41. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, Sato H,. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res 2001; 61: 7985-91.
42. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI,. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65: 8679-89.